Neuraxpharm Group announced that its affiliate Neuraxpharm France has been selected as one of winners for the participation in a pilot program for the medical use of cannabis issued by The French National Agency for the Safety of Medicines and Health Products (ANSM), together with Panaxia Labs,. This selection paves the way for supplying medical cannabis in state-of-the-art formulations to the patient, which will allow the effective start of the pilot program on March 31, 2021 at the latest. Monitoring of compliance and quality of the products supplied will continue throughout the pilot program. The prestigious medical cannabis pilot program intends to provide free products to enrolled patients. It will last two years and provide medical cannabis products to 3,000 patients who meet the determined criteria. Selected doctors, nurses and pharmacists participating in this program will undergo special training in registering and issuing medical cannabis prescriptions to patients. At the end, a decision will be made by the French Authorities regarding a license for the use and sale of medical cannabis products in France.